Mannkind (MNKD) EBT (2010 - 2026)
Mannkind (MNKD) reported EBT of -$16.4 million for Q1 2026, down 220.19% year-over-year from $13.6 million in Q1 2025, and up 21.81% on a QoQ basis from -$20.9 million in Q4 2025.
Mannkind (MNKD) has 17 years of EBT data on file, last reported at -$16.4 million in Q1 2026.
- Quarterly EBT fell 220.19% year-over-year to -$16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.6 million (down 185.97% YoY) and the FY2025 annual result came in at $1.4 million, down 95.39% from the prior year.
- EBT grew to -$16.4 million in Q1 2026 per MNKD's latest filing, from -$20.9 million in the prior quarter.
- Across five years, EBT topped out at $13.6 million in Q1 2025 and bottomed at -$29.0 million in Q2 2022.
- The 5-year median for EBT is -$1.7 million (2024), against an average of -$4.8 million.
- The widest annual swing landed in 2024, when EBT jumped 647.82%; it then sank 347.85% in 2025.
- Tracing MNKD's EBT over 5 years: stood at -$17.9 million in 2022, then soared by 116.5% to $3.0 million in 2023, then surged by 185.11% to $8.4 million in 2024, then slumped by 347.85% to -$20.9 million in 2025, then gained by 21.81% to -$16.4 million in 2026.
- Per Business Quant, the three latest MNKD EBT figures stand at -$16.4 million (Q1 2026), -$20.9 million (Q4 2025), and $7.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | -16.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.37 Mn |
| Dec 31, 2025 | -20.93 Mn |
| Sep 30, 2025 | 7.78 Mn |
| Jun 30, 2025 | 940,000.00 |
| Mar 31, 2025 | 13.62 Mn |
| Dec 31, 2024 | 8.45 Mn |
| Sep 30, 2024 | 12.87 Mn |
| Jun 30, 2024 | -1.69 Mn |
| Mar 31, 2024 | 10.89 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.43 Mn |
| Jun 30, 2022 | -29.02 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -28.06 Mn |
| Sep 30, 2021 | -4.43 Mn |
| Jun 30, 2021 | -35.52 Mn |
| Mar 31, 2021 | -12.92 Mn |
| Dec 31, 2020 | -26.41 Mn |
| Sep 30, 2020 | -11.47 Mn |
| Jun 30, 2020 | -10.25 Mn |
| Mar 31, 2020 | -9.32 Mn |
| Dec 31, 2019 | -13.40 Mn |
| Sep 30, 2019 | -10.37 Mn |
| Jun 30, 2019 | -12.39 Mn |
| Mar 31, 2019 | -14.88 Mn |
| Dec 31, 2018 | -7.22 Mn |
| Sep 30, 2018 | -24.17 Mn |
| Jun 30, 2018 | -22.44 Mn |
| Mar 31, 2018 | -30.39 Mn |
| Dec 31, 2017 | 80.95 Mn |
| Sep 30, 2017 | -32.89 Mn |
| Jun 30, 2017 | -35.34 Mn |
| Mar 31, 2017 | -16.32 Mn |
| Dec 31, 2016 | 53.97 Mn |
| Sep 30, 2016 | 126.52 Mn |
| Jun 30, 2016 | -29.96 Mn |
| Mar 31, 2016 | -24.87 Mn |
| Dec 31, 2015 | 81.03 Mn |
| Sep 30, 2015 | -31.86 Mn |
| Jun 30, 2015 | -28.91 Mn |
| Mar 31, 2015 | -30.66 Mn |
| Dec 31, 2014 | -36.44 Mn |
| Sep 30, 2014 | -36.52 Mn |
| Jun 30, 2014 | -73.37 Mn |
| Mar 31, 2014 | -52.06 Mn |
| Dec 31, 2013 | -53.58 Mn |
| Sep 30, 2013 | -50.82 Mn |
| Jun 30, 2013 | -46.12 Mn |
| Mar 31, 2013 | -40.97 Mn |
| Dec 31, 2012 | -51.78 Mn |
| Sep 30, 2012 | -43.24 Mn |
| Jun 30, 2012 | -36.58 Mn |
| Mar 31, 2012 | -38.17 Mn |
| Dec 31, 2011 | -36.40 Mn |
| Sep 30, 2011 | -38.40 Mn |
| Jun 30, 2011 | -44.48 Mn |
| Mar 31, 2011 | -41.53 Mn |
| Dec 31, 2010 | -38.31 Mn |
| Sep 30, 2010 | -45.30 Mn |
| Jun 30, 2010 | -42.25 Mn |